These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 26338145)

  • 21. Recommended composition of influenza virus vaccines for use in the 2003-2004 influenza season.
    Wkly Epidemiol Rec; 2003 Feb; 78(9):58-62. PubMed ID: 12666272
    [No Abstract]   [Full Text] [Related]  

  • 22. [The results of a study of the data obtained from patients vaccinated earlier with different influenza vaccines].
    Ivanova VT; Slepushkin AN; Burtseva EI; Oskerko TA; Golubeva LI; Beliaev AL
    Vopr Virusol; 1994; 39(2):66-8. PubMed ID: 8017055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.
    Staneková Z; Varečková E
    Virol J; 2010 Nov; 7():351. PubMed ID: 21118546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Antibody functional activity in immunization with influenza vaccines].
    Naĭkhin AN; Artem'eva SA; Ermachenko TA; Vybornykh EN; Kustikova IuG; Doroshenko EV; Katorgina LG; Denisov GM; Kim TN
    Vopr Virusol; 1993; 38(5):204-7. PubMed ID: 8284916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Influenza live attenuated intra-nasal vaccines].
    Weil-Olivier C
    Arch Pediatr; 2010 Jun; 17(6):904-5. PubMed ID: 20654953
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB; Coelingh K; Ambrose CS; Woo JC; Wu X
    Vaccine; 2010 Feb; 28(9):2149-56. PubMed ID: 20003926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?
    Tan J; Asthagiri Arunkumar G; Krammer F
    Curr Opin Immunol; 2018 Aug; 53():45-50. PubMed ID: 29677684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?
    Neu KE; Henry Dunand CJ; Wilson PC
    Curr Opin Immunol; 2016 Oct; 42():48-55. PubMed ID: 27268395
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Platforms for the Development of a Universal Influenza Vaccine.
    Kumar A; Meldgaard TS; Bertholet S
    Front Immunol; 2018; 9():600. PubMed ID: 29628926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H
    Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season.
    Wkly Epidemiol Rec; 2014 Mar; 89(10):93-104. PubMed ID: 24707514
    [No Abstract]   [Full Text] [Related]  

  • 32. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
    Toback SL; Levin MJ; Block SL; Belshe RB; Ambrose CS; Falloon J
    Expert Rev Vaccines; 2012 Nov; 11(11):1293-303. PubMed ID: 23151111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommended composition of influenza virus vaccines for use in the 1995-1996 season.
    Wkly Epidemiol Rec; 1995 Feb; 70(8):53-6. PubMed ID: 7537515
    [No Abstract]   [Full Text] [Related]  

  • 34. Cross-protection of Lactococcus lactis-displayed HA2 subunit against homologous and heterologous influenza A viruses in mice.
    Lei H; Peng X; Zhao D; Jiao H; Ouyang J
    Arch Virol; 2015 Dec; 160(12):3011-9. PubMed ID: 26358264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recommended composition of influenza virus vaccines for use in the 1999-2000 season.
    Wkly Epidemiol Rec; 1999 Feb; 74(8):57-61. PubMed ID: 10079754
    [No Abstract]   [Full Text] [Related]  

  • 36. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence update: GlaxoSmithKline's inactivated quadrivalent influenza vaccines.
    Bekkat-Berkani R; Ray R; Jain VK; Chandrasekaran V; Innis BL
    Expert Rev Vaccines; 2016; 15(2):201-14. PubMed ID: 26641539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The prospects for using inactivated influenza vaccines on the troops].
    Furgal SM; Degtiarev AA; Korol'kov VF
    Voen Med Zh; 1993 May; (5):35-6, 80. PubMed ID: 8356819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
    Settembre EC; Dormitzer PR; Rappuoli R
    J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective Antibodies Against Influenza Proteins.
    Padilla-Quirarte HO; Lopez-Guerrero DV; Gutierrez-Xicotencatl L; Esquivel-Guadarrama F
    Front Immunol; 2019; 10():1677. PubMed ID: 31379866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.